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Introduction: Erlotinib is an epidermal growth factor receptor
tyrosine kinase inhibitor that significantly increases survival for
patients with previously treated advanced non-small cell lung can-
cer. Epidermal growth factor receptor tyrosine kinase inhibitors have
been reported to be particularly effective in Asian patients and may
have a distinct safety profile in this population compared with
non-Asian patients. We report safety and efficacy data from a
subpopulation of East/South-East (E/SE) Asian patients enrolled in
a global, open-label, phase IV trial of erlotinib (Tarceva Lung
Cancer Survival Treatment study).
Methods: Patients who had previously failed on chemotherapy or
radiotherapy, or were unsuitable for these treatments, were treated
with oral erlotinib (150 mg/d) until disease progression or unaccept-
able toxicity.
Results: Best response data were available for 1118 E/SE Asian and
4276 non-E/SE Asian patients. The overall response rates were 27%
versus 10%, respectively (p  0.0001). The disease control rates
were 78% versus 66%, respectively (p  0.0001). Survival data
were available for 1242 E/SE Asian and 5338 non-E/SE Asian
patients. The median progression-free survival times were 5.78
months versus 2.92 months, respectively (hazard ratio  0.66, p 
0.0001). The median overall survival times were 14.7 months versus
6.8 months, respectively (hazard ratio  0.57, p  0.0001). One-
year survival rates were 58.3% and 32.7%, respectively. Safety data
were available for 1242 E/SE Asian patients. Seventeen percent of
these patients experienced one or more erlotinib-related adverse
event (AE) (other than the most frequently occurring AEs prespeci-
fied in the protocol) and 2% experienced an erlotinib-related serious
AE. Dose reductions were reported for 171 (14%) patients.
Conclusion: Erlotinib is an effective and well-tolerated treatment
for Asian patients with advanced non-small cell lung cancer.
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The epidermal growth factor receptor (EGFR) is part of areceptor family linked to a complex intracellular signaling
network, which is central to cellular processes that are rele-
vant to tumor growth, development, and apoptosis inhibition
in non-small cell lung cancer (NSCLC). As such, EGFR is a
rational target for therapeutic intervention in NSCLC. Single-
agent erlotinib is the only EGFR tyrosine kinase inhibitor
(TKI) proven to significantly prolong overall survival (OS) in
patients with NSCLC after failure of cytotoxic chemotherapy.1
In BR.21, a randomized, placebo-controlled, phase III trial in
731 patients with advanced NSCLC who had received at least
one line of chemotherapy, erlotinib (n  488) significantly
prolonged survival, delayed symptom deterioration, and pro-
vided quality of life benefits compared with placebo.1,2
Patients with Asian ethnicity are a population who
respond well to EGFR TKI therapy. Multiple retrospective
studies from Asia report high response rates and impressive
survival duration after treatment with EGFR TKIs.3,4 In two
recent prospective studies of erlotinib and gefitinib, approx-
imately 12% and 20% of the total populations were Asian,
respectively.1,5 In retrospective subgroup analyses of Asian
patients in both studies, median OS was longer with EGFR
TKI therapy than with best supportive care (erlotinib hazard
ratio [HR] 0.7, p  0.01; gefitinib HR 0.66, p  0.01). The
high incidence of exon 19 and 21 EGFR mutations in Asian
populations (49.5% in patients with early-stage resectable
adenocarcinoma and 37.6% in advanced-stage adenocarci-
noma) is the main explanation for these superior outcomes.6,7
By comparison, the EGFR mutation rate in Western popula-
tions is 15 to 17%.8,9 Furthermore, the safety profile of EGFR
TKIs in Asian populations may also be different from that
seen in other populations. For example, the incidence of
interstitial lung disease (ILD) may be higher in Japanese
patients than in other Asian populations.10 This observation
remains to be validated prospectively in an Asian population.
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Erlotinib is approved in more than 80 countries for the
treatment of NSCLC for patients who have received at least
one line of prior chemotherapy. The Tarceva Lung Cancer
Survival Treatment (TRUST) study was a large international,
open-label, phase IV study of erlotinib that was designed to
allow access to erlotinib monotherapy for patients with ad-
vanced stage IIIB/IV NSCLC who had previously failed on,
or were considered unsuitable to receive, standard chemo-
therapy, or radiotherapy, and who were ineligible for other
erlotinib trials. In each country involved, recruitment contin-
ued until erlotinib was granted a license.
Recruitment into the TRUST study ceased as of June
28, 2007. A total of 6665 patients were enrolled into the study
at 513 centers across 51 countries worldwide. Of the 1242
patients recruited within the East/South-East (E/SE) Asian
region (China, Taiwan, Hong Kong, Korea, Thailand, Malay-
sia, and Indonesia), 1241 were of Asian ethnicity. For the
purposes of this analysis, we report data from all 1242
patients who were recruited in the E/SE Asian region to
investigate the hypothesis that treatment outcomes in this
subgroup would be superior to those observed in a largely
non-Asian population (2% of patients recruited in other
regions were Asian). The E/SE Asian population from
TRUST provides the largest prospective data set available to
determine the efficacy and safety of erlotinib in Asian pa-
tients with advanced NSCLC and to explore potential predic-
tive factors for better response and longer survival in this
population.
PATIENTS AND METHODS
Inclusion and Exclusion Criteria
Patients aged 18 years or older with histologically or
cytologically confirmed, unresectable, stage IIIB/IV NSCLC
who had received at least one previous course of standard
chemotherapy or radiotherapy, or were unsuitable for chemo-
therapy (and could not participate in another trial with erlo-
tinib), were eligible for TRUST. Additional criteria included
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0 to 3; an estimated life expectancy of 12 weeks
or more; and adequate hematological, renal, and hepatic
function (serum bilirubin must have been1.5 upper limit of
normal). At least 3 weeks must have elapsed from the last
dose of previous therapy, and patients must have recovered
from any toxic effects of such therapies before enrolment.
Patients who had fully recovered from previous surgery
were eligible. Women of childbearing potential were re-
quired to test negative for pregnancy and agree to birth
control precautions.
Key exclusion criteria included the following: any
evidence of unstable systemic disease (including active in-
fection; grade four hypertension; unstable angina; congestive
heart failure; and hepatic, renal or metabolic disease); prior
treatment with anti-EGFR agents (including small molecules
or monoclonal antibodies); previous malignancies within the
last 5 years (other than cervical carcinoma or skin cancer that
underwent successful treatment); untreated brain metastases
(newly diagnosed or preexisting) or spinal cord compression;
and any significant ophthalmologic abnormalities (including
severe dry eye syndrome, keratoconjunctivitis sicca, Sjo¨gren’s
syndrome, severe exposure keratitis, or any other disorder likely
to increase the risk of corneal epithelial lesions).
The study complied with the Declaration of Helsinki
and Good Clinical Practice guidelines. Informed consent was
obtained from all patients, and the protocol was approved at
all participating centers by respective ethics committees.
Study Design and Treatment
This was a phase IV, open-label, single-arm study. Oral
erlotinib (F. Hoffmann-La Roche, Basel, Switzerland) was
administered once daily at a dose of 150 mg to all patients
until disease progression, unacceptable toxicity, or death.
Dose interruption or reduction (in 50 mg/d decrements) was
permitted in the event of treatment-related adverse events
(AEs). The primary objective was to provide access to erlo-
tinib for patients with stage IIIB/IV NSCLC who had failed
or were unsuitable for chemotherapy/radiotherapy before ap-
proval. Secondary objectives were to assess safety, best
response, progression-free survival (PFS), and OS. The inci-
dence and severity of erlotinib-related rash was also a sec-
ondary end point for this study.
Clinical Assessments
Outcomes included best response as per investigator
assessment (complete response [CR], partial response [PR],
or stable disease [SD]), PFS, OS, and safety. Clinical and
laboratory assessments were conducted at baseline and then
every 4 weeks throughout the study. Tumor response was
assessed using Response Evaluation Criteria in Solid Tumors
(RECIST)11 at least every 2 months (by computerized tomog-
raphy, magnetic resonance imaging, or radiography). For
patients who were classified as having tumor response, a
confirmatory evaluation was carried out 4 weeks after the
initial determination of response.
For safety and tolerability evaluations, AEs and serious
AEs (SAEs) of any cause were assessed and graded using
National Cancer Institute Common Toxicity Criteria (NCI-CTC)
version 3.0. Treatment-related AEs were reported if they
were not included on a list of prespecified AEs defined in the
study protocol (pruritus, dry skin, diarrhea, nausea, vomiting,
stomatitis, abdominal pain, fatigue, dyspnea, cough, anorexia,
infection, conjunctivitis, and keratoconjunctivitis sicca). All
treatment-related SAEs were reported (regardless of whether
the AE was included on the prespecified list). The incidence
and severity of erlotinib-related rash was recorded as a
secondary end point. The incidence and severity of ILD was
recorded by exclusion diagnosis based on investigator assess-
ment according to NCI-CTC version 3.0 (pneumonitis and
pulmonary infiltrates were applicable). All erlotinib-related
AEs or SAEs resulting in treatment withdrawals were re-
corded (regardless of whether the AE was included on the
prespecified list). Erlotinib-related AEs or SAEs leading to
dose reduction or modification were also monitored (unless
they were included in the list of prespecified AEs). In the
event of an erlotinib-related AE that was not controlled by
best supportive care or not tolerated due to any reason
(regardless of severity), dose reductions were permitted (see
above). Within 2 weeks of a dose reduction, erlotinib-related
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toxicity must have improved by 1 NCI-CTC grade and be
NCI-CTC grade 2 (or 1 for ocular toxicity), or a further
dose reduction was required. Dose re-escalation was only
permissible if the reason for reduction was erlotinib-related
rash and if the rash was grade 2.
Statistical Analysis
The overall response rate (ORR) was defined as the
sum of CR and PR. A patient was classified as having SD if
they had a response assessment of CR, PR, or SD at more
than one visit but were not confirmed as having a CR or PR
(SD criteria must be met for 28 days). The disease control
rate (DCR) was defined as the sum of CR, PR, and SD. PFS
was determined from the date of erlotinib initiation until the
date of first documented progression according to RECIST
objective tumor assessment or until the date of death for any
reason in the absence of disease progression. OS was deter-
mined from the date of start of treatment until date of death
(irrespective of cause). Clinical outcomes, including ORR,
DCR, PFS, 1-year survival, and OS, were also available for
the global TRUST non-E/SE Asian population for compari-
son with the TRUST E/SE Asian population. Clinical out-
comes were collected for all E/SE Asian patients, including
those who received erlotinib as first-line treatment.
Differences in OS and PFS according to clinical or
disease characteristics were analyzed using the log-rank test.
Multivariate analyses were performed for PFS and OS using
the Cox regression model and for DCR using the logistic
regression model. Baseline characteristics investigated for the
analyses comprised the following: gender (male/female); age
(65 years/65 years); ECOG PS (PS 0 or 1/PS 2 or 3);
stage (stage IV/stage IIIB); histology (adenocarcinoma or
bronchoalveolar carcinoma [adeno/BAC]/squamous cell car-
cinoma); treatment line (second line/third line); smoking
status (nonsmoker [NS  smoked 100 cigarettes in their
lifetime]/current or former smoker [C/FS  smoked 100
cigarettes in their lifetime]). Given that 1241 of 1242 patients
were Asian, ethnicity was not considered as a baseline factor
in this analysis. Patients with a missing value for any of the
baseline characteristics were excluded from the multivariate
analysis. For PFS, OS, and DCR analyses, factors were
included in the model using a stepwise approach: the criteria
for entry into the model being a p value0.25 and the criteria
for remaining in the model being a p value 0.15.
RESULTS
Patients
Between November 2, 2004, and June 28, 2007, a total
of 6665 patients were enrolled in the TRUST study, including
1345 patients of Asian ethnicity and 5320 patients of non-
Asian ethnicity. The study database was locked (cut-off date)
on April 17, 2009. Of the 1345 Asian patients enrolled in the
TRUST study, we report data from the subpopulation of
patients who were recruited in E/SE Asia (n  1242),
including those from the following seven countries/regions:
mainland China (n  519); Taiwan (n  300); South Korea
(n  201); Hong Kong (n  179); Thailand (n  30);
Indonesia (n  8); and Malaysia (n  5). The E/SE Asian
study population (n  1242) comprised all patients who had
received at least one dose of erlotinib (regardless of whether
major protocol violations occurred). The median duration of
follow-up was 4.57 months (range, 0–37.06 months) for 1239
E/SE Asian patients and 2.20 months (range, 0–43.36) for
5309 non-E/SE Asian patients with a known end date (the
remaining 3 E/SE Asian patients and 29 non-E/SE Asian
patients were not included in this analysis, mainly because
they were lost to follow-up [E/SE Asian patients n  3,
100%; non-E/SE Asian patients n  19, 66%]).
Baseline disease characteristics are summarized in Ta-
ble 1. Over half of the E/SE Asian patients (54%) were male
and 55% were NS. Adenocarcinoma was the most common
histology (70%). Eighty percent of patients had advanced
stage IV disease and 81% had a PS of 0 to 1. Nine percent of
patients were chemonaive, 57% had received one former line
of treatment, and 34% had received two or more lines of prior
treatment. Of the 111 patients who received erlotinib as
first-line therapy, 53% were male, 46% were NS, 65% had
adenocarcinoma, 74% had stage IV disease, and 74% had a
PS of 0 to 1.
Response and Survival
Best response data were available for 1118 E/SE Asian
and 4276 non-E/SE Asian patients, including 21 (2%) E/SE
and 185 (4%) non-E/SE Asian patients who were not evalu-
able because response data were not collected at the first
evaluation, and their tumors were not evaluable for response
at the second evaluation (Table 2). The remaining 124 E/SE
and 1062 non-E/SE Asian patients could not be included in
the response analyses because no best response data were
available (mainly due to symptomatic deterioration [40%] or
patient refusal [23%] in the E/SE population and symptom-
atic deterioration [35%] and death due to malignant disease
[23%] in the non-E/SE Asian population). Both the ORR and
DCR were significantly higher in these patients compared
with non-E/SE Asian patients (n  4276), ORR: 27% versus
10% (p  0.0001); DCR: 78% versus 66% (p  0.0001),
respectively.
PFS was significantly longer in E/SE Asian versus
non-E/SE Asian patients: 5.78 months (n  1242; 95%
confidence interval [CI]: 5.39–6.57) versus 2.92 months (n
5338; 95% CI: 2.79–3.02), respectively (HR 0.66, 95% CI:
0.62–0.70, p  0.0001) (Figure 1A).
Median OS for E/SE Asian versus non-E/SE Asian
patients was 14.7 months (n  1242; 95% CI: 13.8–15.5)
versus 6.8 months (n  5338; 95% CI: 6.5–7.1), respectively
(HR 0.57, 95% CI: 0.53–0.62, p 0.0001) (Figure 1B). At
the time of data cutoff, the 1-year survival rates were 58.3%
(28.3% censored) and 32.7% (16.6% censored), respectively.
Response and Survival in Selected Subgroups
In a separate analysis, response and survival data for
subgroups, defined on the basis of gender, histology (squa-
mous or nonsquamous cell carcinoma), and smoking status
(C/FS or NS), were assessed (data not shown). Females with
adenocarcinoma attained the highest tumor response rates
(42% for C/FSs and 35% for NSs). The lowest DCR (38%)
was observed in the subgroup of male NSs with squamous
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cell carcinoma (no responses were reported); however, there
were only 13 patients in this category. Variability in the DCR
between the other groups ranged from 62% (female NSs with
squamous cell tumors) to 86% (female NSs with nonsqua-
mous cell tumors). Across all subgroups examined, the me-
dian PFS and OS ranged from 1.7 months and 3.9 months
(both in the subgroup of male NSs with squamous tumors) to
9.2 months and 20.3 months, respectively (both in the sub-
group of female NSs with nonsquamous tumors). Median
PFS and OS were generally higher among all female sub-
groups compared with male subgroups.
FIGURE 1. Progression-free survival (A) and overall survival
(B) in TRUST E/SE Asian patients (n  1242) versus TRUST
non-E/SE Asian patients (n  5338).









Age, yr, median (range) 60 (22–87) 63 (19–91)
Gender, n (%)
Male 668 (54) 3306 (62)
Female 574 (46) 2032 (38)
Ethnic origin, n (%)
Caucasian/white 1 (1) 5056 (95)
Asiana 1241 (100) 104 (2)
Otherb 0 (0) 178 (3)
ECOG PS, n (%)
0 204 (16) 1269 (24)
1 803 (65) 2701 (51)
2 181 (15) 1054 (20)
3 54 (4) 306 (6)
No data 0 (0) 8 (1)
Stage, n (%)
Stage IIIB 251 (20) 1125 (21)
Stage IV 991 (80) 4194 (79)
Other 0 (0) 15 (1)
No data 0 (0) 4 (1)
Histology, n (%)
Adenocarcinoma 867 (70) 2723 (51)
Bronchoalveolar carcinoma 32 (3) 340 (6)
Large cell carcinoma 12 (1) 370 (7)
Squamous cell carcinoma 221 (18) 1331 (25)
Other 110 (9) 571 (11)
No data 0 (0) 3 (1)
Prior lines of chemotherapy, n (%)
None 111 (9) 758 (14)
One 704 (57) 2520 (47)
Two 420 (34) 2008 (38)
Other 7 (1) 52 (1)
Smoking status, n (%)
NS 689 (55) 1315 (25)
C/FS 553 (45) 4014 (75)
No data 0 (0) 9 (1)
a Includes patients from China, Taiwan, Hong Kong, Korea, Thailand, Malaysia,
and Indonesia.
b Includes patients with “Indian” ethnicity.
TRUST, Tarceva Lung Cancer Survival Treatment; E/SE, East/South-East; ECOG
PS, Eastern Cooperative Oncology Group performance status; NS, nonsmoker; C/FS,
current or former smoker.




(n  1118), n (%)
Non-E/SE Asian
Population
(n  4276), n (%)
Complete response (CR) 9 (1) 36 (1)
Partial response (PR) 295 (26) 373 (9)
Objective response rate
(ORR  CR  PR)
304 (27) 409 (10)
Stable disease (SD) 571 (51) 2421 (57)
Disease control rate
(DCR  CR  PR  SD)
875 (78) 2830 (66)
Progressive disease (PD) 222 (20) 1261 (29)
Not evaluable (NE) 21 (2) 185 (4)
Total (CR  PR  SD 
PD  NE)
1118 (100) 4276 (100)
Remaining patients in the study
population for whom no
best response data were
available, mainly due to
124 1062
Symptomatic deterioration 49 (40) 375 (35)
Patient refusal 28 (23)
Death due to malignant
disease
— 247 (23)
a Only the two most frequently reported reasons are listed.
TRUST, Tarceva Lung Cancer Survival Treatment; E/SE, East/South-East.
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Multivariate Analyses
Multivariate analyses were performed using the Cox re-
gression model for PFS and OS and using the logistic regression
model for DCR (Table 3). For both the PFS and OS analyses,
data were available for 1022 E/SE Asian patients, with 220
patients excluded because of missing data. For the PFS analysis,
113 patients had not experienced progression at the last obser-
vation, and their data were therefore censored. The model for
PFS was optimized to include the following characteristics:
smoking status, baseline ECOG PS, and histology. In this
population, NSs who had a baseline ECOG PS of 0/1 and
adeno/BAC histology were more likely to experience longer
PFS compared with patients in other subgroups. For the OS
analysis, data were censored for the 301 patients who were still
alive at last contact. The optimal model for OS included gender
in addition to the characteristics mentioned above. Females,
NSs, with a baseline ECOG PS of 0/1, and adeno/BAC histol-
ogy were more likely to experience longer survival compared
with patients in other subgroups. For both the PFS and OS
optimal models, the factors mentioned above were shown to be
statistically significant (p  0.05). For the DCR analysis using
the logistic regression model, data were available for 930 pa-
tients of whom 730 experienced disease control. A further 312
patients were excluded because of missing data. The optimal
model for DCR included smoking status and histology; NSs
with adeno/BAC histology were more likely to experience
disease control. Both these factors were shown to be statistically
significant (p  0.05) by logistic regression analysis.
Of particular interest is the subgroup of E/SE Asian
patients who received erlotinib as first-line therapy. Of 111
patients, 37% were NSs with adenocarcinoma and approxi-
mately 26% of the first-line therapy group had poor PS (PS
2/3), with a median age of 72 years, compared with 60 years
in the overall E/SE Asian population. The tumor response
rate in this population was 31%, and the median OS was 11.5
months (95% CI: 7.6–14.3).
Efficacy data for patients with erlotinib-related rash were
available for all 1242 E/SE Asian patients. Of these, 1021
patients (82%) experienced rash of any grade (36% grade 0 to 1,
46% grade 2 to 4). Median OS for patients with erlotinib-related
rash of grade 2 to 4 was 19.5 months (95% CI: 17.8–21.1)
versus 12.2 months for patients with grade 0 to 1 rash (95% CI:
10.6–13.6, HR  0.60; p  0.0001) (Figure 2).
Safety and Tolerability
Safety data were available for all 1242 E/SE Asian pa-
tients of whom 532 (43%) had one or more AE regardless of
causality. Seventeen percent of patients experienced an erlo-
tinib-related AE (other than the most frequently occurring AEs
predefined in the protocol; Table 4); of these patients, 87% had
an AE that was grade 1 or 2 in severity. Only 31 (2%) patients
had an SAE considered to be related to treatment. These in-
cluded gastrointestinal disorders (diarrhea or abdominal pain)
and skin and subcutaneous tissue disorders (includes rash; Table
5). ILD occurred in two patients (0.16%); one patient had grade
2 ILD that resolved spontaneously and the other patient had
grade 4 ILD that did not improve despite treatment withdrawal.
TABLE 3. Multivariate Analyses for PFS, OS, and DCR
Factor (Cox Regression Model) HR 95% CI p
Factors for PFS (n  1022)
Histology (SCC: adeno/BAC) 1.66 1.40–1.98 0.001
Smoking status (C/FS: NS) 1.46 1.27–1.68 0.001
ECOG PS (2 or 3: 0 or 1) 1.27 1.07–1.50 0.0058
Factors for OS (n  1022)
ECOG PS (2 or 3: 0 or 1) 1.80 1.50–2.16 0.0001
Histology (SCC: adeno/BAC) 1.72 1.43–2.06 0.0001
Gender (male: female) 1.32 1.08–1.63 0.0075
Smoking status (C/FS: NS) 1.32 1.07–1.63 0.0094
Factor (Logistic Regression Model) Odds Ratioa 95% CI p
Factors for DCR (n  930)
Smoking status (C/FS: NS) 1.61 1.15–2.26 0.0058
Histology (SCC: adeno/BAC) 1.54 1.03–2.29 0.0348
a For response: no response.
PFS, progression-free survival; OS, overall survival; DCR, disease control rate;
SCC, squamous cell carcinoma; adeno, adenocarcinoma; BAC, bronchoalveolar carci-
noma; HR, hazard ratio; CI, confidence interval; C/FS, current or former smoker; NS,
nonsmoker; ECOG PS, Eastern Cooperative Oncology Group performance status.
FIGURE 2. Overall survival according to rash (grade 0/1
versus grade 2; n  1186).
TABLE 4. Erlotinib-Related Adverse Events (Any Grade)a






Patients with any erlotinib-related AE 207 (17) 27 (2)
Gastrointestinal disorders 34 (3) 0 (0)
Mouth ulceration 24 (2) 0 (0)
Infections and infestations 79 (6) 6 (1)
Paronychia 75 (6) 3 (1)
Investigations 55 (4) 3 (1)
Alanine aminotransferase increased 17 (1) 2 (1)
Aspartate aminotransferase increased 15 (1) 1 (1)
Blood bilirubin increased 21 (2) 1 (1)
Nervous system disorders 16 (1) 0 (0)
Skin and subcutaneous tissue disorders 27 (2) 3 (1)
Blood and lymphatic system disorders 15 (1) 4 (1)
Eye disorders 14 (1) 1 (1)
Respiratory, thoracic, and mediastinal
disorders
15 (1) 5 (1)
a As defined by NCI-CTC criteria v3.0.
b Other than the most frequently occurring pre-specified events.
AE, adverse event; NCI-CTC, National Cancer Institute Common Toxicity Criteria.
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This patient subsequently had respiratory failure and died. Both
cases were considered to be erlotinib related.
Dose reductions were reported for 171 patients (14%);
164 (13%) of these patients required a dose reduction due to
erlotinib-related AE. The majority (71%) of the 171 dose reduc-
tions were necessitated by an erlotinib-related skin rash. Another
10 patients required a dose reduction for diarrhea (1%), and
one patient required a dose reduction for hepatic dysfunction
(hyperbilirubinemia;1%). The majority of all dose reductions
(167 patients; 13%) were to 100 mg/d, with only 22 (2%)
patients requiring further reduction to 50 mg/d. AEs resulting in
treatment withdrawal occurred in 31 (2%) patients; all AEs and
groups of AEs (by body system) that resulted in treatment
withdrawal occurred in 1% of patients. Three (1%) patient
deaths occurred due to a treatment-related event; one patient
each due to pneumonia (grade 3), pneumonitis (grade 3), and
respiratory failure (grade 5).
DISCUSSION
We confirm the superior outcomes with erlotinib in this
patient population, compared with the TRUST overall global
population (includes E/SE Asian and non-E/SE Asian patients)
(Reck et al., unpublished data). The median PFS for the E/SE
Asian population was 5.78 months compared with 2.92 months
for the non-E/SE Asian population and 3.25 months for the
overall global population (Reck et al., unpublished data). The
median OS was 14.7, 6.8, and 7.9 months, respectively (Reck et
al., unpublished data). The ORR was significantly higher for the
E/SE Asian patients (27%), compared with the non-E/SE Asian
patients (10%) or the overall global population (13%) (Reck et
al., unpublished data). The conclusions from the study must be
tempered by the limitations of the open-label, nonplacebo-
controlled, single-arm study design.
In this study, 111 patients (9%) received erlotinib as
first-line therapy, compared with 13% of the overall global
population (Roche, data on file). In the E/SE Asian patients, we
found no significant differences in PFS between patients who
received erlotinib as first-line treatment, compared with those
who received erlotinib as second-/third-line treatment. This find-
ing supports data from Spanish patients with known EGFR
mutation status where tumor response rates to erlotinib as first-
and second-line therapy were 73.5% and 67.4%, respectively
(p  0.35). In these patients, there were also no significant
differences in PFS and OS between those receiving first-line
erlotinib and those receiving second-line erlotinib.9 In patients
who received first-line erlotinib therapy, we report a tumor
response rate of 31% and a median survival time of 11.5 months.
Patients who receive first-line therapy would usually be ex-
pected to have better survival outcomes than those treated
second-line therapy or later. In our study, the most likely
explanation for the shorter median OS in this subgroup (11.5
months) compared with the overall E/SE Asian population (14.7
months) is that most of these patients were not eligible for
chemotherapy because of advanced age and/or poor PS. Patients
who are preselected on the basis of poor PS may have shorter
survival with EGFR TKI therapy.12,13
Multivariate analyses for PFS and OS showed that smok-
ing status (NS), histology (adeno/BAC), and gender (females)
were all predictive of longer survival with erlotinib. The benefit
obtained in these patients, in addition to E/SE Asian patients
who received first-line erlotinib therapy, is likely to be driven by
the presence of higher rates of EGFR mutations. In subgroup
analyses based on gender, smoking status, and histology, all
subgroups including C/FS, males, and patients with squamous
cell histology obtained a survival benefit with erlotinib. Patients
in these subgroups are less likely to harbor activating EGFR
mutations.14 This finding is compatible with SATURN data in
which patients with EGFR wild-type disease obtained a survival
benefit with erlotinib compared with placebo.15 However, the
reason for such benefit remains to be explored.
This analysis of TRUST is the first study that establishes
skin rash as a predictive factor for improved PFS and OS with
erlotinib in an Asian population. The PFS and OS for patients
who experienced grade 2 rash was found to be significantly
longer than that for patients experiencing grade 0/1 rash. This
finding is consistent with the TRUST global population (Reck et
al., unpublished data; Roche, data on file) and is supportive of
the suggested link between the grade of rash and the efficacy of
EGFR inhibitor-based therapy.16,17 Although skin rash was the
major toxicity in our study, it is crucial that Asian patients who
develop skin rash continue to receive erlotinib therapy, beca-
use they are the population that obtain the greatest benefit from
this therapy. Active and vigorous management of skin rash are
therefore an essential aspect of treatment.
No new safety signals were identified in this study. Be-
cause the prespecified expected treatment-related AEs were not
recorded (unless they resulted in premature treatment with-
drawal), it is not possible to comment on the frequency or
severity of these events. However, the results reported here
support the favorable safety profile of erlotinib seen in previous
clinical trials. Despite reports of a higher risk of ILD in Japanese
patients, we found that the incidence of ILD in the E/SE Asian
population was low and similar to that observed in the global
population (1% in both cases) (Reck et al., unpublished data).
TABLE 5. Erlotinib-Related Serious Adverse Eventsa (Any






Patients with any erlotinib-related
SAE
31 (2) 26 (2)
Gastrointestinal disorders 8 (1) 7 (1)
Abdominal pain 2 (1) 2 (1)
Diarrhea 4 (1) 3 (1)
General disorders and administration
site conditions
4 (1) 3 (1)
Infections and infestations 4 (1) 3 (1)
Respiratory, thoracic and mediastinal
disorders
5 (1)b 3 (1)
Pneumonitis 2 (1) 2 (1)
Skin and subcutaneous tissue
disorders
8 (1) 6 (1)
Rash 6 (1) 4 (1)
a As defined by NCI-CTC criteria v3.0.
b One grade 5 event occurred (respiratory failure).
SAE, serious adverse event; NCI-CTC, National Cancer Institute Common Toxicity
Criteria.
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In summary, our data from more than 1200 E/SE Asian
patients confirm the role of erlotinib in the management of
NSCLC in this population. The superior outcomes compared
with the non-E/SE population are likely to be driven by the
higher EGFR mutation rate in the Asian population. These
results complement data from the overall global population and
confirm the favorable safety profile of erlotinib.
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